What is the average MRD lead time across subtypes?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Unlock essential insights into hereditary cancer risk, diagnosis, and treatment. Study comprehensive strategies with flashcards and multiple-choice questions featuring detailed explanations. Prepare effectively for your exam!

Multiple Choice

What is the average MRD lead time across subtypes?

Explanation:
Minimal residual disease (MRD) refers to the tiny number of cancer cells that remain after treatment and can be detected with sensitive assays. The MRD lead time is the interval from starting therapy to when MRD status becomes detectable or shows a change during monitoring. Across subtypes, treatment courses typically span roughly a year, with MRD assessments often performed after induction and consolidation phases. This makes about 12 months the common, average lead time across subtypes. While individual cases vary, a year captures the central tendency for when MRD changes are most often observed in diverse subtypes.

Minimal residual disease (MRD) refers to the tiny number of cancer cells that remain after treatment and can be detected with sensitive assays. The MRD lead time is the interval from starting therapy to when MRD status becomes detectable or shows a change during monitoring. Across subtypes, treatment courses typically span roughly a year, with MRD assessments often performed after induction and consolidation phases. This makes about 12 months the common, average lead time across subtypes. While individual cases vary, a year captures the central tendency for when MRD changes are most often observed in diverse subtypes.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy